中文

News Center

Targeting the Heart Failure Blue Ocean, Huadong Medicine's DR10624 Selected for National Science and Technology Major Project, Multi-Indication Strategic Blueprint Emerges

2026/08/13

Read more

DR10624 Selected for the 2026 National Science and Technology Major Project "Innovative Drug Development for Heart Failure" – Project Kick-off Meeting Successfully Held

2026/08/13

Read more

Pharma Sources Exclusive: Doer Biologics COO Dr. Fang Yongliang Unveils the Therapeutic Potential and Clinical Development of Triple Agonist DR10624

2026/07/23

Read more

Doer Biologics' Global First-in-Class Triple Agonist DR10624 Receives China IND Approval for HFpEF/HFrEF

2026/07/14

Read more

EASL China Voice: DR10624 Phase II Results Show Significant Liver Fat Reduction and Metabolic Improvements in Severe Hypertriglyceridemia

2026/06/03

Read more

EASL 2026 | Doer Biologics Presents Results from a Phase 2 Study of DR10624 in Severe Hypertriglyceridemia on Liver Fat and Improvement of Hepatic Metabolic Markers

2026/05/28

Read more

AACR 2026｜Doer Bio Presents DR319-DP, a Bispecific Bipayload ADC, Demonstrating Breakthrough Potential in Overcoming Efficacy and Resistance Challenges in Solid Tumors

2026/05/25

Read more

Doer Biologics Honored as Hangzhou Quasi-Unicorn for Sixth Consecutive Year

2026/04/24

Read more

AACR 2026 | Doer Biologics Presents Preclinical Data on Bispecific Dual-Payload ADC

2026/04/16

Read more

Doer Biologics to Present Preclinical Results of DR319 Project at AACR 2026

2026/03/24

Read more